UNSPSC 51384200: Nonsteroidal anti inflammatory phenylpropionates

Nonsteroidal anti inflammatory drugs made from carboxylic acids composed of phenyl and propanoic acid.

UNSPSC 51384200 Nonsteroidal anti inflammatory phenylpropionates is a Class code that does not match the work actually being solicited under it in recent state and local opportunities. The nominal scope describes a specific class of anti-inflammatory medications, but the recent contract opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical and OTC product distribution — categories outside the phenylpropionate drug family. The code shows minimal relevant recent activity aligned with its stated scope.

The three most recent opportunities under this code span different issuing bodies and procurement phases. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as an exploratory market-intelligence solicitation to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels, with no formal award value or timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The geographic spread reflects isolated activity in Florida, Texas, and Minnesota through cooperative purchasing, but the code itself appears to be a data-quality issue rather than an active procurement category for phenylpropionate-specific medications.